InvestSMART

Immutep Limited (ASX: IMM) - Announcements

- Current share price for IMM : $0.023

ASX company news and announcements for Immutep Limited (IMM) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immutep Limited (IMM) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immutep Limited (IMM), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immutep Limited (IMM)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$34 Immutep receives A$1.9M from French R&D tax cash rebate 21 Aug 2018 4:51PM $0.035 $0.023 fallen by 34.29%
$34 Immutep to present at BioCentury NewsMakers conference 16 Aug 2018 4:36PM $0.034 $0.023 fallen by 32.35%
$34 TACTI-mel Patient Recruitment Complete & Operational Update 7 Aug 2018 9:28AM $0.036 $0.023 fallen by 36.11%
$34 Immutep secures Canadian patent grant for IMP731 antibody 7 Aug 2018 9:01AM $0.036 $0.023 fallen by 36.11%
$34 Immutep receives IND approval from US FDA for IMP321 31 Jul 2018 9:48AM $0.034 $0.023 fallen by 32.35%
$34 Appendix 4C - quarterly 30 Jul 2018 6:13PM $0.034 $0.023 fallen by 32.35%
$34 Immutep submits IND application with FDA 2 Jul 2018 11:23AM n/a $0.023 n/a
$34 Immutep Investor Update 19 Jun 2018 9:56AM $0.034 $0.023 fallen by 32.35%
$34 Mid-point of patient enrolment reached in AIPAC trial 19 Jun 2018 8:36AM $0.034 $0.023 fallen by 32.35%
$34 Immutep Poster Presentations at ASCO 4 Jun 2018 8:22AM $0.038 $0.023 fallen by 39.47%
$34 Webcast slides for TACTI-mel clinical trial data 30 May 2018 7:30AM $0.031 $0.023 fallen by 25.81%
$34 New Data from Ongoing TACTI-mel Study 30 May 2018 7:30AM $0.031 $0.023 fallen by 25.81%
$34 3rd Annual Advances in Immuno-Oncology Congress Presentation 25 May 2018 4:46PM $0.033 $0.023 fallen by 30.30%
$34 Webcast to discuss interim results from TACTI-mel 17 May 2018 6:23PM $0.027 $0.023 fallen by 14.81%
$34 Response to ASX Price Query 15 May 2018 3:28PM $0.027 $0.023 fallen by 14.81%
$34 Immutep to present at ASCO 4 May 2018 5:12PM $0.025 $0.023 fallen by 8%
$34 Appendix 4C - quarterly 23 Apr 2018 8:21AM $0.023 $0.023 fallen by 0%
$34 Appendix 3B 13 Apr 2018 10:31AM $0.024 $0.023 fallen by 4.17%
$34 Completion of Share Purchase Plan 13 Apr 2018 10:00AM $0.024 $0.023 fallen by 4.17%
$34 Operational Update 3 Apr 2018 8:40AM $0.023 $0.023 fallen by 0%
$34 Cambridge Healthtech Institute's I-O Summit Presentation 23 Mar 2018 9:01AM $0.024 $0.023 fallen by 4.17%
$34 Patient dosing commences in additional TACTI-mel cohort 22 Mar 2018 8:46AM $0.024 $0.023 fallen by 4.17%
$34 Becoming a substantial holder from AEF 19 Mar 2018 4:37PM $0.023 $0.023 fallen by 0%
$34 Disclosure Under Listing Rules 3.10.5A and 7.1A.4(b) 14 Mar 2018 5:45PM $0.025 $0.023 fallen by 8%
$34 Appendix 3B & Cleansing Notice 14 Mar 2018 5:25PM $0.025 $0.023 fallen by 8%

751 - 775 of 790 results

Page 31 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.